Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study

INTRODUCTION: Nintedanib (NTD) has been shown to be effective in systemic sclerosis (SSc)-interstitial lung disease (ILD). Here we describe the efficacy and safety of NTD in a real-life setting. METHODS: Patients with SSc-ILD treated with NTD were retrospectively evaluated at 12 months prior to NTD...

Descripción completa

Detalles Bibliográficos
Autores principales: Campochiaro, Corrado, De Luca, Giacomo, Lazzaroni, Maria-Grazia, Armentaro, Giuseppe, Spinella, Amelia, Vigone, Barbara, Ruaro, Barbara, Stanziola, Anna, Benfaremo, Devis, De Lorenzis, Enrico, Moccaldi, Beatrice, Bosello, Silvia Laura, Cuomo, Giovanna, Beretta, Lorenzo, Zanatta, Elisabetta, Giuggioli, Dilia, Del Papa, Nicoletta, Airo, Paolo, Confalonieri, Marco, Moroncini, Gianluca, Dagna, Lorenzo, Matucci-Cerinic, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Systemic Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950968/
https://www.ncbi.nlm.nih.gov/pubmed/36813476
http://dx.doi.org/10.1136/rmdopen-2022-002850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950968/
https://www.ncbi.nlm.nih.gov/pubmed/36813476
http://dx.doi.org/10.1136/rmdopen-2022-002850

Ejemplares similares